title: Use of B7 costimulatory molecules as adjuvants in a prime-boost vaccination against Visna/Maedi ovine lentivirus.
abstract: RNA transcripts of the B7 family molecule (CD80) are diminished in blood leukocytes from animals clinically affected with Visna/Maedi virus (VMV) infection. This work investigates whether the use of B7 genes enhances immune responses and protection in immunization-challenge approaches. Sheep were primed by particle-mediated epidermal bombardment with VMV gag and env gene recombinant plasmids together with plasmids encoding both CD80 and CD86 or CD80 alone, boosted with gag and env gene recombinant modified vaccinia Ankara virus and challenged intratracheally with VMV. Immunization in the presence of one or both of the B7 genes resulted in CD4+ T cell activation and antibody production (before and after challenge, respectively), but only immunization with CD80 and CD86 genes together, and not CD80 alone, resulted in a reduced number of infected animals and increased early transient cytotoxic T lymphocytes (CTL) responses. Post-mortem analysis showed an immune activation of lymphoid tissue in challenge-target organs in those animals that had received B7 genes compared to unvaccinated animals. Thus, the inclusion of B7 genes helped to enhance early cellular responses and protection (diminished proportion of infected animals) against VMV infection.
authors.affiliation: CSIC-Public University of Navarra, Pamplona, Spain.
authors.forename: X
authors.initials: X
authors.lastname: de Andrés
authors.forename: R
authors.initials: R
authors.lastname: Reina
authors.forename: J
authors.initials: J
authors.lastname: Ciriza
authors.forename: H
authors.initials: H
authors.lastname: Crespo
authors.forename: I
authors.initials: I
authors.lastname: Glaria
authors.forename: H
authors.initials: H
authors.lastname: Ramírez
authors.forename: M J
authors.initials: MJ
authors.lastname: Grilló
authors.forename: M M
authors.initials: MM
authors.lastname: Pérez
authors.forename: V
authors.initials: V
authors.lastname: Andrésdóttir
authors.forename: S
authors.initials: S
authors.lastname: Rosati
authors.forename: M
authors.initials: M
authors.lastname: Suzan-Monti
authors.forename: L
authors.initials: L
authors.lastname: Luján
authors.forename: B A
authors.initials: BA
authors.lastname: Blacklaws
authors.forename: G D
authors.initials: GD
authors.lastname: Harkiss
authors.forename: D
authors.initials: D
authors.lastname: de Andrés
authors.forename: B
authors.initials: B
authors.lastname: Amorena
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D018122:B7-1 Antigen / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology; D051940:B7-2 Antigen / Q000008:administration & dosage / Q000235:genetics / Q000494:pharmacology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D015686:Gene Products, env / Q000008:administration & dosage / Q000235:genetics; D015683:Gene Products, gag / Q000008:administration & dosage / Q000235:genetics; D005822:Genetic Vectors; D007117:Immunization, Secondary / Q000379:methods; D008297:Male; D011021:Pneumonia, Progressive Interstitial, of Sheep / Q000517:prevention & control*; D012756:Sheep; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology*; D014616:Vaccinia virus / Q000235:genetics; D014765:Viral Vaccines / Q000276:immunology*; D014790:Visna-maedi virus / Q000235:genetics / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D015686:Gene Products, env; D015683:Gene Products, gag; D019444:Vaccines, DNA; D014765:Viral Vaccines